Table 2.
Characteristics of CHD patients by coronary stenosis severity.
| Characteristic | Coronary artery stenoses | ||
|---|---|---|---|
| mild | medium | severe | |
| Number in category | 41 | 132 | 141 |
| Number of subjects (%) | |||
| Women | 18 (43.9) | 46 (34.8) | 48 (34.0) |
| Smokers | 12 (29.3) | 77 (58.3) | 76 (53.9) |
| Drinking alcohol | 11 (26.8) | 44 (33.3) | 41 (29.1) |
| Hypertension | 28 (68.3) | 84 (63.6) | 94 (66.7) |
| Antihypertensive treatment | 34 (82.9) | 99 (75.0) | 114 (80.9) |
| Dyslipidemia | 113 (73.4) | 106 (80.3) | 115 (81.6) |
| Statins treatment | 33 (80.5) | 114 (86.4) | 119 (84.4) |
| Diabetes mellitus | 19 (46.3) | 26 (19.7) | 51 (36.2) |
| Myocardial infarction | 3 (13.1) | 24 (42.9) | 29 (51.8) |
| Mean (SD) of characteristic | |||
| Age (years) | 62.0 (8.2) | 59.6 (10.5) | 63.0 (11.1) |
| Systolic pressure (mm Hg) | 138.8 (16.9) | 134.4 (19.5) | 134.3 (16.8) |
| Diastolic pressure (mm Hg) | 80.9 (11.0) | 80.1 (13.0) | 79.3 (11.9) |
| Mean arterial pressure (mm Hg) | 100.2 (11.8) | 98.2 (13.5) | 97.6 (11.9) |
| Heart rate (beats per minute) | 76.0 (12.5) | 74.8 (14.4) | 74.5 (11.2) |
| Biochemical data | |||
| Serum creatinine (μmol/L) | 71 (59–76) | 72 (63–83) | 78 (66–88)† |
| eGFR (mL/min/1.73 m2) | 90.8 (13.1) | 90.2 (16.1) | 83.9 (17.6)† |
| Serum triglyceride (mmol/L) | 1.58 (0.92–2.12) | 1.57 (1.12–2.18) | 1.48 (0.99–1.92) |
| Total cholesterol (mmol/L) | 3.98 (0.76) | 4.46 (0.93)† | 4.40 (1.13)† |
| LDL cholesterol (mmol/L) | 2.48 (0.70) | 2.88 (0.78)† | 2.85 (0.98)* |
| HDL cholesterol (mmol/L) | 1.00 (0.22) | 1.08 (0.27) | 1.03 (0.20) |
| Fasting blood glucose (mmol/L) | 6.74 (2.34) | 6.12 (2.46) | 6.74 (3.35) |
| γ-glutamyltransferase (units/L) | 21 (15–31) | 26 (20–37) | 22 (16–32) |
| uric acid (μmol/L) | 304.5 (84.5) | 327.4 (82.6) | 344.1 (91.2)* |
| Apolipoprotein A-I (μg/mL) | 8.90 (1.85) | 8.65 (2.01) | 8.97 (2.11) |
| Apolipoprotein B (μg/mL) | 200.9 (45.3) | 200.0 (51.7) | 204.2 (50.1) |
| Inflammation markers | |||
| HSPC (%) | 0.04 (0.03–0.09) | 0.07 (0.03–0.13)† | 0.07 (0.04–0.14)§ |
| C-reactive protein (mg/L) | 1.10 (0.79–2.98) | 1.56 (0.90–4.59) | 1.90 (0.90–6.20)* |
| GM-CSF (ng/L) | 105.5 (21.7) | 107.6 (21.9) | 109.7 (22.7) |
| SDF-1α (pg/mL) | 3530.7 (612.6) | 3553.9 (657.1) | 3579.3 (653.6) |
| WBC count (x109/L) | 6.85 (1.91) | 7.97 (2.83)† | 7.68 (2.72) |
| Neutrophils (x109/L) | 4.38 (1.51) | 5.35 (2.56)† | 5.15 (2.52)* |
| Monocytes (x109/L) | 0.48 (0.22) | 0.50 (0.20) | 0.50 (0.19) |
| Lymphocytes (x109/L) | 1.77 (0.54) | 1.92 (0.89) | 1.83 (0.71) |
| Coagulation markers | |||
| Fibrinogen (g/L) | 2.93 (2.42–3.26) | 3.13 (2.73–3.57) | 3.20 (2.69–3.70) |
| D-dimer (mg/L) | 0.11 (0.07–0.16) | 0.10 (0.06–0.16) | 0.11 (0.07–0.19) |
| Circulating HSPCs (%) | 0.06 (0.02–0.07) | 0.10 (0.03–0.13)* | 0.11 (0.04–0.14) |
The extent of CHD was defined by the number of significant coronary artery stenoses. Myocardial infarction included both ST-elevated and non-ST-elevated myocardial infarction. eGFR: estimated glomerular filtration rate. HSPCs: hematopoietic stem/progenitor cells. Logarithmically transformed values are expressed as geometric means (interquartile range). Means were compared using t-test and ANOVA and proportions by Fisher’s exact test. Significance of the difference when compared with the mild group: *P ≤ 0.05; †P ≤ 0.01.